Sedative composition reducing affectivity accompanying oestrus in cats and dogs

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science. A sedative composition with reducing affectivity accompanying oestrus for dogs and cats contains in one dose per 10 kg of animal's body weight: theanine - from 5 to 100 mg, tryptophane - from 2 to 16 mg.

EFFECT: composition normalises the animals' behaviour for 30 minutes - 1 hour after application.

6 ex

 

The invention relates to veterinary medicine and animal nutrition.

Known veterinary drugs, feed additives and other products for animals, which has calming and anti-stress effect, which use including when the excitement caused by the sexual hunt (Stop stress, cat Bayun and others). They contain as active substances of different groups of compounds (plant extracts, paramonotone substances). However, these means are not enough fast action and arousal are mainly used as additional tools.

Also known group of drugs and supplements for animals with regulating sexual hunt (and/or contraceptive action (for example, Contresens, Stop sex and others) that contains hormones and hormone-like substances. However, they, in turn, do not have anti-stress, calming and improves the mood of the animal action. In addition, this group of funds have unwanted side effects.

The closest analogue of the invention are chewable tablets for dogs and cats "Anxitane® (production Corporation Virbac, France), containing as active substance the amino acid L-theanine. Tablets promote relaxation, relieve nervousness, anxiety, stress (L. Kern. La transmission e la peur. In: La Communication. Collection Zoopsychiatrie, Beata C. ed. Marseille, Solal Editeurs, 2005).

L-Theanine - an amino acid, which is part of "Anxitane®", has a calming and neuroprotective effects in laboratory animals (Vlasov So on, Barkovsky A. A., Zukhurov M And Zwerina C. M. mechanisms of the neuroprotective effect of a component of green tea is L-theanine/ Regional circulation and microcirculation. - 2010. No. 4. - S. 67-71).

It is widely known use of L-theanine as a sedative in the composition of feed additives, dietary supplements, sports nutrition, and food products.

However Anxitane® does not reduce arousal during sexual hunting cats and dogs and has a long course of application to achieve a calming effect.

The objective of the invention is the creation on the basis of the amino acid L-theanine sedative for cats and dogs, which has, unlike analogue, quick and effective action including when engaging in hunting.

To achieve the technical result was studied compositions based on amino acids L-theanine and additional calming components, in particular glycine, tryptophan, ginger and Valerian root.

For testing have been made an experimental batch of feed additives in the form of tablets containing different compositions. Funds were given orally in the dosage of 1 tablet is per 10 kg of animal body weight once between feedings.

The tests were carried out for each composition of 10 cats and 10 dogs of different age, sex and different breeds that are in stressful situations (exhibitions, visits to the veterinarian and others), and in the excitement caused by the sexual hunt. The results are presented in the examples below.

Example 1

Composition No. 1

Theanine 50 mg

Glycine 10 mg

Excipients (lactose, starch, cheese whey, talc) and flavour - 0.3,

Tests showed the sedative effect of the composition only in cases when the arousal caused by the presence of estrous or sexual arousal. The song had a calming effect have 4 cats that were in the period of sexual hunting, and 2 males in a state of sexual arousal.

Example 2

Composition No. 2

Theanine 50 mg

Ginger - 45 mg,

The Valerian root 45 mg

Auxiliary substances and flavour - 0.3,

This composition had a soothing effect in 36% of the animals after applying for 3 times a day. Had hardly any action on animals in arousal.

Example 3

Composition No. 3

Theanine 50 mg

Tryptophan - 8 mg

Auxiliary substances and flavour - 0.3,

Compo is ice had a long good calming effect. Animal behavior returned to normal within 30 minutes to 1 hour after ingestion of the tablets in all animals and remained normal during the day of observation.

Example 4

Composition No. 4

Theanine 5 mg

Tryptophan - 2 mg

Auxiliary substances and flavour - 0.3,

This composition had a calming effect on all animals, but the effect was less pronounced and not long.

Example 5

Composition No. 5

Theanine 100 mg

Tryptophan - 16 mg

Auxiliary substances and flavoring additives to 0.3, the Use of this composition was also reassured all animals, but have side effects, in particular the part of the animals were in a dream state.

Example 6

Composition No. 6

Theanine 50 mg

Tryptophan - 8 mg

Distilled water, stabilizer, preservative, flavoring additive to 5 ml

The solution was applied at a dose of 5 ml per 10 kg of body weight. Tests showed that in the form of a solution composition is not less effective than solid form, and has a calming effect on all animals.

Thus, only the combination of two amino acids, theanine and tryptophan, has a fairly rapid calming effect (from 30 to 60 minutes) and displays a new action - namely, a pronounced suppression of excitation caused sexual hunts the th.

L-Tryptophan is an essential amino acid, which, along with other amino acids is widely used as feed additives for balancing rations of farm and domestic animals. Also known soothing feed additive containing tryptophan (Equilizer (France)) for horses with severe stress and anxiety.

It is established that peptides containing tryptophan (8 g/100 g) at a dose of 0.01-0.02 g/kg body weight cause widespread effects in laboratory animals for 30-40 minutes (EN 2043364, 10.09.1995).

However, it is not established that the tryptophan reduces sexual arousal during sexual hunting animals.

As follows from the examples, all tested dosages theanine and tryptophan sufficient to achieve the stated technical result, but the best is a composition comprising theanine 50 mg and tryptophan - 8 mg per 10 kg of animal body weight.

The term "Theanine" (L-theanine, 1-tianin, 1-Theanine, 1-teanin) of the present invention is an amino acid, a derivative of glutamic acid (γ-glutamyl ethylamide), derived mainly from tea leaves, as well as synthetic and microbiologically. You can use any form amino acids L-theanine, D-theanine and DL-theanine, but it is preferable to use L-shape. Theanine is really from the briteney can be applied in the form of amino acids, and green tea extract.

The tryptophan of the present invention may be a 1-tryptophan, 5-hydroxy-tryptophane, extracts of plants containing tryptophan and its derivatives, and other biologically active form of tryptophan and its derivatives obtained by different methods.

The composition is effective in tablet form and in the form of a solution, and can be used in the composition of medicines, feed additives and feed products for cats and dogs.

Soothing song with a decreasing arousal action for dogs and cats containing one dose per 10 kg of animal body weight:
theanine is from 5 to 100 mg
tryptophan is from 2 to 16 mg



 

Same patents:

FIELD: biotechnology.

SUBSTANCE: invention is a composition having antibacterial, immunostimulating, anti-allergic and anti-inflammatory action, containing bacterial waste products useful for human body, in the form of exometabolites and fermentolysis products, characterised in that it is a culture medium of lactic acid bacteria, containing laxarane in an amount of 5-10 g/ml, caseicyne, isracydine or their mixture and lectins in an amount of 0.05-2.5 mol/l, histamine in an amount of 0.8-2.0 mmol/l and monocarboxylic fatty acid with an unbranched chain, namely, acetic acid, propionic acid, butyric acid and valeric acid - in an amount of 10-20 mg/ml.

EFFECT: expanding the range of agents having complementary antibacterial, immunomodulating, anti-allergic and anti-inflammatory action.

4 cl, 5 ex

FIELD: medicine.

SUBSTANCE: in the process of preoperative preparation imunofan is introduced to a patient intramuscularly in a dose of 1 ml one time per day. After that, laparoscopy with revision of the abdominal cavity organs, opening of the omental bursa and its washing with solutions of antiseptics, and formation of the external cholecystoma are performed. Intraoperatively at the stage of the omental bursa drainage and before performing cholecyctomy, into the stomach introduced is a thin probe for enteral nutrition, through which early intraoperative nutrition is realised by introduction of liquid food "Diason" at a rate of 30 ml/hour in an amount of 450-500 ml on the first day of the postoperative period. In the postoperative period introduction of imunofan in the same dose is continued for 9 days. Introduction of "Diason" food through the thin probe is also continued on the second day of the postoperative period at a rate of 30 ml/hour in an amount of 450-500 ml, on the third day at a rate of 45-60 ml/hour in an amount of 700-750 ml, on 4 and 5 day at a rate of 80-90 ml/hour in an amount of 950-1000 ml, from 6 to 9 days at a rate of 125-150 ml/hour in an amount of 1500-2000 ml. On the 10-th day after operation the probe of enteral nutrition is removed. After that, a seeping type of nutrition is realised, in the process of which a drink supportan or nutridrink is introduced to the patient in an amount of 200 ml 3-4 times per day until complete recovery of the trophological status.

EFFECT: method provides prophylaxis of purulent-inflammatory complications due to the prevention of impairment of cellular and humoral immunity and sufficient correction of the trophological status, contributing to a considerable increase of life quality of the operated patient.

3 ex

FIELD: biotechnologies.

SUBSTANCE: invention proposed N-end fragment of soluble suppressor of immune response with the length of 21 amino-acids, which has sequence of amino-acids as per Seq ID NO: 1, allowing to promote formation of regulatory T-lymphocytes, as well as a promotion method of formation of regulatory T-lymphocytes with N-end fragment of soluble suppressor of immune response with Seq ID NO: 1, at its introduction with the concentration of 0.1-50 microgram/ml.

EFFECT: invention can be used for propagation of regulatory T-lymphocytes obtained from a patient suffering autoimmune disease, for the purpose of further injection of the obtained T-lymphocytes into the body of the patient.

3 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology and can be applied for treatment of traumatic and dystrophic injuries of eye cornea. For this purpose peptide fragments of protein S100b - SP2 and/or SP3 in concentrations 10-6 M are introduced in conjunctive cavity or in endonasal way. Introduction is realised daily two times per day during 10 days.

EFFECT: method ensures fast and high-quality restoration of injured zone of cornea due to stimulation of regenerative-reparative processes in cornea.

3 ex, 2 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biochemistry. A biomass of the gram-negative bacteria Salmonella typhi fam. Enterobacteriacea is prepared. A cell wall peptidoglycane (CWP) of the bacteria is recovered by biomass extraction in 45% aqueous phenol at temperature 70-90°C or in aqueous solution of ionic or non-ionic detergents at temperature 37-100°C. That is followed by preparative enzymatic hydrolysis for insoluble CWP cleavage with the use of lysozyme at pH 4.5 - 8.9 and temperature 10 - 37°C. Simultaneously, a pharmacologically acceptable mixture of substances is removed by dialysis from the reaction mixture with the use of semipermeable membranes for ultrafiltration with cut-off size up to 5 kDa. The mixture of substances is also recovered by means of column gel-chromatography, particularly preparative gel chromatography on Sephadex or TSK gel columns. The end product yield is 320 mg.

EFFECT: method enables producing the pharmacologically acceptable mixture of substances containing the following ingredients: β-N-acetyl-D-glucosaminyl-(1→4)-N-acetyl-D-muramoyl-(L-alanyl-D-isoglutaminyl-meso-diaminopimelic acid) (GMtri); β-N-acetyl-D-glucosaminyl-(1→4)-N-acetyl-D-muramoyl-(L-alanyl-D-isoglutaminyl-meso-diaminopimeloyl-D-alanine) (GMtetra); and GMtetra dimer (diGMtetra) wherein a bond of monomer residues of GMtetra is enabled by a carboxyl group of terminal D-alanine of one GMtetra residue and ω-aminogroup of meso-diaminopimelic acid of the other GMtetra residue with the coupled tetrapeptide resides positioned in various polysaccharide chains.

4 cl, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of invention refers to ophthalmic compositions containing protease inhibition peptide substrates. The ophthalmic compositions contains a peptide substrate in a solution in the amount of approximately 0.01 wt/vol. % to 10 wt/vol. %, and said substrate is specified in a group consisting of gelatin, ovomacroglobulin, collagen and casein in an ophthalmically acceptable carrier. The composition additionally contains galactomannan and borate. The invention also describes a method for using the composition for treating dry eye.

EFFECT: group of invention provides higher viability and lower water loss of corneal epitheliocytes.

12 cl, 12 dwg, 11 ex

FIELD: medicine.

SUBSTANCE: composition for treatment and/or prevention of infection with gastrointestinal pathogens and/or disease of mammals, associated with infection by said pathogens, contains lipid, protein and hydrocarbon part, where lipid part provides from 5 to 50% of total number of calories, protein part provides from 5 to 50% of total number of calories and carbohydrate part provided from 15 to 90% of total number of calories. Protein part contains: (i) pea protein hydrolysate and (ii) at least one source of nitrogen, selected from the group, consisting of milk proteins, milk protein hydrolysate, egg protein and egg protein hydrolysate.

EFFECT: application of claimed composition in mixture composition makes it possible to increase efficiency of treatment or prevention of infection with gastrointestinal pathogens, in particular, Helicobacter pylori, or disease of mammals, associated with said pathogen infection.

1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: group of invention refers to a polypeptide composition containing one or more polypeptides which are immunogenic in a vertebrate so that they induce production in the vertebrate of cells of the immune system able to recognize at least one epitope in a protein fraction of arthropod's saliva with the protein fraction of arthropod's saliva having weight of 20 kDa or less, while the polypeptides are independently specified in a polypeptide sequence SEQ ID NO:1-44 or having 7 amino acids or more partial sequences, methods for making it, using for preparing a drug.

EFFECT: group of invention is effective in treating or preventing a disease propagated by arthropods.

44 cl, 10 dwg, 21 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to abdominal surgery and oncology, and may be used for treating patients with tumour intestinal obstruction. The method involves gastrointestinal decompression, active lavage, enterosorption, enteral nutrition. The enteral therapy is intraoperative. The minimum early enteral nutrition is prescribed on the first postoperative day and thereafter; adequate tolerance of the probe nutrition and the presence of minimum excretion allows alternation of various formulae for enteral nutrition. On the first postoperative day, a monomer formula with added 20% Nutriene Elemental 200 ml is introduced. On the second day, Nutriene Elemental is introduced in the volume of 10 kcal/day. On the third day, Nutrisone Standard is introduced in the volume of 15 kcal/day. On the forth day, the formula Nutrisone Energia with dietary fibres is introduced in the volume of 20 kcal/day. On the fifth day, after the nasointestinal probe has been removed and unassisted stool is observed, Pevzner's therapeutic diet No.1 which is added by the introduction of the formula Nutrisone Energia with dietary fibres by sipping method.

EFFECT: method provides clinical effectiveness including ensured by correction of protein-calorie and intestinal insufficiency in the patients with acute intestinal obstruction of tumour aetiology.

1 tbl, 2 ex

FIELD: food industry.

SUBSTANCE: invention is related to food industry and may be used for food allergy prevention. Hydrolysed by fermentative method egg whites with hydrolysis degree from 15% to 28% are applied in production of food compositions.

EFFECT: invention ensures tolerance to egg whites contained in food products with mammals.

5 cl, 5 dwg, 6 ex

FIELD: biotechnology, biochemistry.

SUBSTANCE: invention relates to producing the biologically active complex eliciting antioxidant and immunomodulating activity and used in medicine, cosmetics, veterinary science and food industry. The biologically active complex preparing by enzymatic hydrolysis of muscle tissue represents complex of biologically active compounds involving carnosine and anserine in the amount 85-97 wt.-% of the native content of these components in poultry muscle tissue, 1-7 weight parts of amino acids, 0.5-12 weight parts of oligopeptides of molecular mass 10 kDa, not above, and 0.1-15 weight parts of cyclic and polycyclic phenolic compounds as measured for 1 weight part of carnosine and anserine in the complex. This complex is prepared by enzymatic hydrolysis of milled and homogenized water muscle tissue in preferable dilution homogenate with water in the range 0.2-0.6 and with using proteolytic enzymes in the amount 2-5 wt.-% of the protein content and working at pH 4.5-8.5 and at enhanced temperature being preferably at 45-65°C. Product is isolated as extract or powder prepared in drying the extract. Invention provides enhancing effectiveness of the claimed complex.

EFFECT: improved method for preparing, valuable properties of complex.

7 cl, 6 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vestibular and auditory disorders, trigeminal nerve's neuralgia and peripheral paresis of facial nerve of herpetic etiology. The method deals with introduction of an antiherpetic preparation followed by immunomodelling therapy with the use of polyoxidonium. Moreover, after treating with antiherpetic preparation before introducing polyoxidonium it is necessary to conduct additional successive therapy: with preparations of trophic action as milgamma or neuromultivit at simultaneous introduction of antioxidant, then comes intratissue injection of cerebrolysine being behind the top of mastoid process.

EFFECT: the innovation enables to decrease the quantity of relapses due to stopping the development of herpes simplex virus, restore conductivity along nervous fiber and improve endoneural circulation.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves applying antiherpetic therapy using Phamcyclovir. Then, Trental is sequentially introduced during 5 days with 2-5 ml of cerebrolysin being concurrently intratissularly introduced behind mastoid process tip. Mexidol is administered for 10 days. The treatment is finished by introducing Polyoxydonium.

EFFECT: combined microcirculation improvement; high neurotrophic and antioxidant activity; secondary immune deficiency adjustment; eliminated labyrinth hydrops.

FIELD: medicine, neurology, in particular treatment of disseminated sclerosis.

SUBSTANCE: complex therapy includes plasma exchange, interferonotherapy, administration of copaxon, cytostatics, symptomatic and bracing agents, and cyclosporin A. Administration of steroids is excluded. Additionally ceruloplasmine intravenously drop-by-drop in dose of 100 mg and cerebrolysate intramuscularly in dose of 10 ml for 10 days are administered. Claimed method provides stable remission up to 12 months for 89.2 % of patients.

EFFECT: decreased invalidisation due to reconstitution of regulatory relationship between nervous and immune systems.

1 ex, 1 tbl

FIELD: medicine, neurology, pediatrics.

SUBSTANCE: method involves administration of aminolone in the dose 0.25-0.5 g, 2-3 times per a day for 6-8 months, cerebrolysine in the dose 1.0-1.2 ml by intramuscular route, course 15-20 injections, mydocalm in the dose 50-75 mg, 2 times per a day for 1-1.5 month, vitamin B12 in the dose 150-300 mcg, course 15-20 injections wherein injections of vitamin B12 and cerebrolysine are alternated in each other day; in 1.5 month after onset of this treatment prefizone in the dose 1 ml by intramuscular route is administrated every day, course 15-20 injections, pyrogenal in the dose 100-200 MTD is administrated by course 15-20 injections and curative physical culture is carried out with heat procedure in sauna (dry bath) for 3 months, and after termination of medicinal therapy hyppotherapy is carried out for 3-5 months for each other day. Method allows straightening the kyphoscoliotic carriage and to improve joins mobility due to increase of the motions volume in them. Invention can be used in treatment of spastic diplegia in infantile cerebral paralysis.

EFFECT: improved treatment method.

3 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: after termination of surgery operation as to strabismus the method involves catheterization of Tenon's space by using the irrigative system for the successive fractional administration of preparations of riboflavin, cerebrolysin, dicynone, caffeine, emoxipine and taufon in the dose 0.3 ml for each drug. Also, method involves carrying out the computer training by designation of the complex "Shooting range/gallery" and "Pursuit" wherein the patient combines color symbols that change colors and sizes in cyclic change of positions, 1 séance for each type of exercise every day. Administration of drugs and computer trainings are carried out for 10 days. Such performance of the method provides the effective treatment of strabismus and recovery of binocular vision based on the complex effect on all links of coordination activity of sensor and motor eye apparatus. Invention can be used in treatment of strabismus.

EFFECT: improved and effective method of treatment.

2 ex

FIELD: veterinary, in particular agents for prophylaxis and treatment of gastric diseases in calves.

SUBSTANCE: the fist foremilk of calved in summer cows is collected, filtered, bottled in sterile 1 l vessels and frozen in freezing apparatus at 20-22°C. In winter-spring period foremilk is defrosted and conserved with potassium sorbate in ratio of 2.5 ml of 40 % potassium sorbate solution per 1 l of foremilk.

EFFECT: environment friendly method for stimulation of calves immunity.

3 tbl

FIELD: medicine, biochemistry, pharmacy, biotechnology.

SUBSTANCE: invention relates to a method for preparing polyelectrolyte microparticles containing the end substance and showing sensitivity to alteration of the environment composition. Method involves preparing oppositely charged polyelectrolytes on microaggregates containing an encapsulated substance. These polyelectrolyte microparticles can be used both in medicine as systems used in delivery drugs and providing pH-sensitive release of encapsulated substance and in biotechnology as biocatalysts stabilized with respect to unfavorable conditions. Invention provides preparing polyelectrolyte microparticles characterizing by the high content of active substance - up to 90% of microparticles mass. Proposed method is sample and involves lesser amounts of steps.

EFFECT: improved preparing method.

9 cl, 3 tbl, 2 dwg, 61 ex

FIELD: medicine.

SUBSTANCE: method involves applying mono therapy with Cerebrolysin intramuscularly introduced once a day in the morning at a daily dose of 0.1 ml/kg of weight as 20 days long course or Encephabol to be taken 3 times a day in 30 min after having taken meals. Encephabol is given at a dose of 50 mg in 2-5 years old children cases or at a dose of 100 mg in 6-10 years old children cases. Male children take Encephabol in not longer than 10 days long course. Female children take Encephabol in a course being longer than 10 days.

EFFECT: enhanced effectiveness of genome instability adjustment.

6 dwg

FIELD: medicine.

SUBSTANCE: method involves applying nutritive probe support with 1-2% Pecto solution in Rehydron at a dose of 30.0-50.0 ml per one feeding session 6-7 times a day beginning in 24-48-h from receiving injury. Daily quantity of introduced solution is gradually increased to 500.0 ml. Then, semi-element food mixtures are introduced in 20% dilution from a standard one at a dose of 30.0-60.0 ml per one feeding session with 2.0-2.5 h long pause 7 times a day. Mixture dilution is gradually increased to standard one and volume to 1500-2000 ml. Pecto introduction is continued as solution of 5.5 g per 50.0 ml of water at a dose of 5.0-20.0 ml per 20 min before every probe-mediated feeding.

EFFECT: enhanced effectiveness in supporting energetic and plastic organism needs; avoided stress ulcer formation.

Up!